title: Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?
authors.affiliation: Institut für Herzinfarktforschung an der Universität Heidelberg, c/o Klinikum Ludwigshafen, Bremserstrasse 79, 67063 Ludwigshafen, Germany.
authors.forename: Harm
authors.initials: H
authors.lastname: Wienbergen
authors.forename: Jochen
authors.initials: J
authors.lastname: Senges
authors.forename: Anselm K
authors.initials: AK
authors.lastname: Gitt
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control*; D048909:Diabetes Complications / Q000453:epidemiology / Q000517:prevention & control*; D003925:Diabetic Angiopathies / Q000453:epidemiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D040242:Risk Reduction Behavior
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin